Hardi Mundl

Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome

Gregory G. Schwartz, Anders Olsson, Markus Abt et al. · New England Journal of Medicine · 2012 · 2K citations · Full text

Medicine, Cardiology, Pharmacology +17

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Jonathan P. Piccini, Valeria Caso, Stuart J. Connolly et al. · The Lancet · 2022 · 311 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +11

Fasting Triglycerides Predict Recurrent Ischemic Events in Patients With Acute Coronary Syndrome Treated With Statins

Gregory G. Schwartz, Markus Abt, Weihang Bao et al. · Journal of the American College of Cardiology · 2015 · 287 citations

Medicine, Cardiology, Pharmacotherapy +13

Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial

E. Magnus Ohman, Matthew T. Roe, Philippe Gabríel Steg et al. · The Lancet · 2017 · 219 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation

Jeff S. Healey, David J. Gladstone, Balakumar Swaminathan et al. · JAMA Neurology · 2019 · 207 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17